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Abstract
Background: Thyroid nodules are common among adults though only a small percentage is malignant, which can
histologically mimic benign nodules. Accurate diagnosis of these thyroid nodules is critical for the proper clinical
management.
Methods: We investigated immunoexpression in 98 surgically removed benign thyroid nodules including 52
hyperplastic nodules (HN) and 46 follicular/Hurthle cell adenomas (FA), and 54 malignant tumors including 22
follicular carcinoma (FC), 20 classic papillary carcinoma (PTC), and 12 follicular variant papillary carcinoma (FVPC).
Results: The staining results showed that malignant tumors express galectin-3, HBME-1, CK19 and Ret oncoprotein
significantly more than benign nodules. The sensitivity of these markers for the distinction between benign and
malignant lesions ranged from 83.3% to 87%. The sensitivity of two-marker panels was not significantly different.
Immunoexpression was usually diffuse and strong in malignant tumors, and focal and weak in the benign lesions.
Conclusion: Our findings indicate that these immunomarkers are significantly more expressed in malignant tumors
compared to benign lesions and may be of additional diagnostic value when combined with routine histology.
Introduction
Thyroid tumors are the most common endocrine
tumors in the United States, and about 40% of the
population between 30 and 60 years-old have thyroid
nodules, most of which are benign [1]. Difficulties in the
diagnosis of follicular patterned thyroid lesions on fine
needle aspiration (FNA) cytology examination are well
know problems, and histologic evaluation of surgically
resected follicular patterned lesions can be challenging
as well. One common diagnostic dilemma is encoun-
tered when an encapsulated lesion with follicular growth
pattern has some but not all the nuclear features diag-
nostic of papillary thyroid carcinoma [2-6]. Also, follicu-
lar neoplasms are classified as benign or malignant
depending on the presence or absence of capsular and/
or vascular invasion. However, evaluation of these fea-
tures can be challenging on histologic examination due
to the presence of incomplete capsular penetration or
equivocal vascular invasion, and for this reason, many
end up with a general inconclusive diagnosis of “follicu-
lar lesion” [1,2].
The treatment and post-operative management of var-
ious types of thyroid nodules depends on the FNA cyto-
logic and/or histologic diagnosis. It is estimated that
only about 10% of the resected lesions are proven to be
malignant [7]. Furthermore, the surgical approach of
these lesions may cause anxiety and social distress, and
may incur high cost for the healthcare system [8].
Currently, the standard diagnosis depends on the his-
tomorphologic features of routine hematoxylin and
eosin (H&E) stained slides, but interobserver or intraob-
server disagreements in the diagnosis of follicular thyr-
oid lesions are well known and documented [3]. For
example, in a recent study, review of 200 thyroid tumors
by seven Italian pathologists showed good agreement for
papillary and anaplastic carcinomas, moderate for
medullary and poor for follicular thyroid carcinomas.
Recent studies have focused on identifying IHC mar-
kers that can help in differentiating benign from malig-
nant lesions, and follicular variant of papillary
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Several markers have been investigated on aspiration
biopsy material and histologic specimens such as CK19,
galectin-3, HBME-1, CK 903, CITED1, Ret oncoprotein,
CD 44, CD 57, cyclin D1 and p27. The findings were
generally encouraging and promising although some stu-
dies demonstrated inconclusive or conflicting results
[3,5,6,8,9,12,13,17-23].
The aim of this study was to investigate the ability of
four IHC markers, individually or in combination, to dis-
tinguish between benign (non-neoplastic and neoplastic)
and malignant (follicular and papillary carcinomas) thyroid
lesions removed by surgical resection. The markers
included galectin-3, HBME-1, CK19 and Ret oncoprotein.
Materials and methods
A total of 152 cases of surgically resected thyroid lesions,
during the period of 2004-2008, were collected from the
archive of the pathology department at Sinai-Grace Hospi-
tal/Detroit Medical Center, Detroit, Michigan. The cases
included 52 benign non-neoplastic lesions diagnosed as
hyperplastic colloid nodules or cellular colloid nodules
(HN), 46 cases of benign tumors (FA/HA) and 54 cases of
malignant tumors (22 cases of FC, 20 cases of PTC and 12
cases of FVPC). Cases with equivocal features or indefinite
diagnosis were excluded from the study. The diagnosis of
hyperplastic colloid nodules was based on the presence of
follicles containing colloid and lined by bland follicular
cells with basal small round nuclei lacking crowding, over-
lapping or other PTC-type nuclei. Clinically, these patients
had elevated serum T3 and/or T4 levels and decreased
thyroid-stimulating hormone levels. The evaluation and
classification of the thyroid tumors was based on WHO
thyroid tumor classification published in 2004. The diag-
nosis of follicular adenoma was made based on the pre-
sence of encapsulated mass with homogenous follicular
proliferation, lack of PTC nuclear features and absence of
vascular and/or capsular invasion. Hurthle cell adenomas
were defined as encapsulated tumor forming solid and
small follicle growth patterns with the presence of more
than 75% of the characteristic large cells with granular
eosinophilic cytoplasm. The diagnosis of classic PTC was
based on the presence of papillary structures with fibro-
vascular cores and specific nuclear features widely known
as typical of papillary carcinoma. The FVPC was diagnosed
based on the presence of follicular growth pattern with
classic PTC-type nuclear features in at least several areas
of the tumor. Follicular carcinoma was diagnosed based
on the presence of follicular proliferation with complete
thick capsule and full capsular penetration and/or vascular
invasion, and atypical hyperchromatic nuclei that lacked
features of PTC nuclei. One case of frankly invasive type
of follicular carcinoma involving the parafollicular tissues
was included.
All specimens were fixed in 10% zinc formalin,
embedded in paraffin and 4 micron-thick sections
stained with hematoxylin and eosin for routine histolo-
gical examination. Immunohistochemical staining was
performed using four selected markers that have been
shown in recent studies to be favorably expressed in
malignant thyroid tumors [9,17-23]. Table 1 shows the
characteristics of the used antibodies including CK19,
HBME-1, and Galectin-3 and Ret oncoprotein. All
immunohistochemical stains were performed on a Ven-
tana Benchmark automated strainer. After standard pro-
tocols for deparaffinization of the 4 micron-thick
sections, and microwave antigen retrieval, the tissue sec-
tions were incubated with available commercial mono-
clonal antibodies diluted at 1: 100, except for Ret
oncoprotein that used 1: 40 dilution, for 32 minutes.
The staining was completed using a streptavidin-biotin-
complex detection method. Positive controls were his-
tiocytes for galectin-3, mesothelioma for HBME-1, skin
for CK19 and a known case of PTC for Ret oncoprotein.
The stained slides were examined by two pathologists
(HS, BJ) blindly and independently without knowing the
original histologic diagnosis. A case was considered
positive for a particular marker when cytoplasmic or
nuclear staining of 10% or more of the lesional cells was
found reactive with the antibody. The staining results
were then correlated with the original histologic diag-
noses and data tabulated. Table2 shows the histologic
diagnosis of the cases with the staining results for each
group of the thyroid lesions.
Interpretation and Analysis: Galectin-3 displayed cyto-
plasmic and nuclear staining, HBME1 staining was cyto-
plasmic with membranous accentuation, CK19 staining
was cytoplasmic and Ret oncoprotein staining was cyto-
plasmic. With HBME-1 marker, only cells with distinct
strong membranous staining were counted as positive
reaction. A lesion was considered positive when 10% or
more of the cells showed reactivity for the specific anti-
body. Sensitivity, specificity, positive predictive value
(PPV) and negative predictive value (NPV) were calcu-
lated for each of the markers and for different combina-
t i o n so ft h e s em a r k e r si nt h eb e n i g nv s .m a l i g n a n t ,
benign non-neoplastic vs. malignant and benign neo-
plastic vs. malignant groups. We chose these parameters
rather than the p-value b e c a u s ew ew e r ei n t e r e s t e dp r i -
marily in finding out the most sensitive and specific
markers. The calculation was done using a known statis-
tical computer software program (SPSS 10.0 for Win-
dows; SPSS Inc. Chicago, Illinois, USA).
Results
Table 2 shows summary of the immunohistochemical
expression of each marker in each group of the thyroid
lesions. In general, high percentages of the malignant
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d i f f u s er e a c t i v i t yf o ra l lm a r k e r s ,w h i l eb e n i g nl e s i o n s
(both neoplastic and non-neoplastic) showed lower
expression with mainly focal and weaker staining. Speci-
fically, benign tumors (FA/HA) were less often positive
than malignant, and the reactivity was less intense.
Benign non-neoplastic lesions (HN) were often negative
but some showed focal weak reactivity.
Table 3 shows the sensitivity, specificity, PPV and
NPV in the malignant tumors (FC, PTC and FVPC) vs.
all benign lesions (HN, FA/HA). All four markers had
very good sensitivity ranging from 83.3% (Ret oncopro-
tein) to 87% (HBME-1), but the specificity was mostly
moderate and ranged from 64.3% (for HBME-1) to
72.4% (for galectin-3).
Non-neoplastic lesions (HN)
Of the 52 cases, only 8 (15.3%) were positive for Galec-
tin-3 and CK19, and 9 (17.3%) positive for Ret and
HBME-1 (Figures 1, 2, 3, 4). Table 2 shows significant
differences in the immunoexpression of all markers in
the benign non-neoplastic (HN) lesions, adenomas and
carcinomas ranging from mid 20%s (HN) to mid 40%s
(adenomas) to mid 80%s (carcinoma).
Adenomas
Of the 46 adenomas, 19 (41.3%) were positive for galec-
tin-3, 21 (45.6%) for Ret, 26 (56.5%) for HBME-1, and
23 (50%) for CK19. As a group, the adenomas appeared
less often positive than carcinomas for each of the four
markers (Table 2) (Figures 5, 6, 7, 8). The data in Table
2 and table 4 shows that immunoexpression of all mar-
kers is much lower in the adenomas than that in carci-
nomas (mid 40s compared to mid 80s). The sensitivity
of the immunoexpression differences of these markers
between adenomas and carcinomas is high ranging from
83.3% (Ret) to 85.2% (galectin-3 and CK19) to 87%
(HBME-1) (Table 4). However, the specificity is only
moderate for the distinction of adenomas from carci-
noma by all markers ranging from 43.5% (HBME-1) to
58.7% (galectin-3).
Carcinomas
of all 54 malignant tumors, 46 (85.1%) were positive for
galectin-3 and CK19, 45 (83.3%) were positive for Ret
and 47 (87%) positive for HBME-1. FC had high rate of
reactivity especially for CK19 (19/22, 86.3%), but also
for galectin-3 and HBME-1 (18/22, 81.8%) and for Ret
(16/22, 72.7%) (Figures 9, 10, 11, 12). Classic PTC
showed 90% (18/20) expression for galectin-3, Ret and
HBME-1, while 17/20 (85%) were positive CK 19 (Fig-
ures 13, 14, 15, 16). FVPC was also highly reactive for
HBME-1 and Ret (11/12, 91.6%), and for galectin-3 and
CK19 (10/12, 83.3%) (Figures 17, 18, 19, 20). The data
shows that all markers have high sensitivity for these
subtypes of malignant thyroid tumors and therefore they
do not reliably distinguish between them.
T a b l e5s h o w st h a t ,a sag r o u p ,t h e r ea r es i g n i f i c a n t
differences in expression between non-neoplastic and
Table 1 Characteristics of the antibodies used
Antibody Clone Dilution Antigen retrieval Company
CK19 RCK108 1:100 HIER EDTA Buffer Dako Corp
HBME HBME-1 1:50 HIER EDTA Buffer Dako Corp
Galectin 3 9C4 1:100 HIER Citrate Buffer Leica Microsystems
Ret Oncoprotein 3F8 1:40 HIER EDTA Buffer Leica Microsystems
Dako Corporation, Carpentaria, California
Leica Microsystems, Bannockburn, Illinois
CK19: cytokeratin 19
Table 2 Correlation of immunohistochemical staining results with histological diagnosis of thyroid lesions
Markers Benign (98) Malignant
(54)
Non-Neoplastic HN
52 (%)
Neoplastic
FA/HA
46 (%)
Total
98 (%)
FC
22
PTC
20
FVPC
12
Total
54 (%)
Gal-3 8 (15.3%) 19 (41.3%) 27(27.5%) 18
(81.8%)
18
(90%)
10
(83.3%)
46
(85.1%)
RET 9 (17.3%) 21 (45.6%) 30(30.6%) 16
(72.7%)
18
(90%)
11
(91.7%)
45
(83.3%)
HBME-1 9 (17.3%) 26 (56.5%) 35(35.7%) 18
(81.8%)
18
(90%)
11
(91.7%)
47
(87%)
CK-19 8(15.3%) 23 (50%) 31(31.6%) 19
(86.3%)
17
(85%)
10
(83.3%)
47
(85.1%)
HN: hyperplastic/adenomatoid nodule; FA: Follicular adenoma; HA: Hurthle cell adenoma; FC: Follicular carcinoma; PTC: Papillary thyroid carcinoma; FVPC:
Follicular variant of papillary carcinoma
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tin-3 and CK19, and 82.7% for Ret and HBME-1. The
differences in percentage reactivity between HN and
malignancy were as follow: 15.3% vs. 85.1% for galectin-
3, 17.3% vs. 83.3% for Ret, 17.3% vs. 87% for HBME-1
and 15.3% vs. 85.1% for CK19 (Table 2).
Value of combined markers expression in benign vs.
malignant lesions
Table 6 demonstrates that, as a group, the application of
the panels of galectin-3+ HBME-1; galectin-3+ CK19, or
HBME-1 +CK19 does not significantly increases the
sensitivity or specificity for the distinction of benign vs.
malignant thyroid lesions. The sensitivity of these mar-
kers combinations was as follows: 85.2% for (galectin-3+
CK19) and 86.1% for (galectin-3+HBME-1) and (HBME-
1+ CK19). Furthermore, the combination panel of all
three markers (galectin-3+ HBME-1+ CK19), surpris-
ingly, did not add to the sensitivity and was only 85.8%.
Similarly, the specificity of these various markers combi-
nations, did not improve over single marker specificity
and showed similar values ranging from 66.3% (HBME-
1+ CK19), to 68.4% (galectin-3+ HBME-1) to 70.4% for
(galectin-3+ CK19). The specificity of the three markers
combination (galectin-3+ HBME-1+ CK19) was also
similar at 68.4%.
Discussion
The current standard in the diagnosis of thyroid lesions
is by histologic examination of routine H&E stained sec-
tions. However, it is widely known that the interpreta-
tion of follicular patterned lesions can be quite difficult
[1,3,5,6,22,24]. A somewhat common dilemma is
encountered with encapsulated tumors showing follicu-
lar growth pattern. Presence or absence of capsular and/
or vascular invasion distinguishes benign from malig-
nant follicular tumors, but identification of this finding
can be challenging due to incomplete capsular penetra-
tion, equivocal vascular invasion or technical difficulties
due to processing or sectioning artifacts. Another chal-
lenging situation is encountered when some but not all
of the diagnostic nuclear features of papillary carcinoma
Table 3 Sensitivity, specificity, PPV and NPV of all Benign
vs. Malignant Thyroid Lesions for each of the IHC
markers
Markers Sensitivity Specificity PPV NPV
Gal-3 0.852 0.724 0.630 0.899
Ret 0.833 0.694 0.600 0.883
HBME-1 0.870 0.643 0.573 0.900
CK-19 0.852 0.684 0.597 0.893
Gal-3, galectin-3; Ret, Ret oncoprotein; CK19, cytokeratin 19; PPV, positive
predictive value; NPV, negative predictive value.
Figure 1 Immunohistochemical stain of hyperplastic colloid
nodule shows the cells are negative for galectin-3 (100×).
Figure 2 Immunohistochemical stain of hyperplastic colloid
nodule shows the cells are negative for Ret oncoprotein
(100×).
Figure 3 Immunohistochemical stain of hyperplastic colloid
nodule shows the cells are negative, for HBME-1 (100×).
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torial review by J. Rosai [4] pointed clearly to this issue.
Thyroid nodules are fairly common clinical findings
affecting approximately 40% of the population between
3 0a n d6 0y e a r so l di nt h eU . S . A . ,a n dt h y r o i dc a n c e ri s
the most common endocrine malignancy [8,13,26,27].
Fortunately, most of these nodules are benign tumors or
hyperplastic lesions; however, it is important to identify
these benign lesions for proper management and to rea-
lize maximum benefit for the patients [28]. Accurate
diagnosis then is very critical for post-operative manage-
ment of patients with thyroid nodules, and incorrect
interpretation can lead to significant psychological and
social problems, and unnecessary increase in healthcare
cost [15,17-19,29,30]. Additionally, since FNA cytology
in itself is not a reliable method to differentiate between
benign and malignant follicular tumors or lesions, these
patients usually undergo surgical resection, although
only about 10% will actually have malignant tumors.
For all of the aforementioned reasons, investigators
have focused during the last several years on finding
molecular or IHC markers that can help in the distinc-
tion between benign and malignant lesions of the thyr-
oid [1,9-11,14,19,21,31-33]. Identifying markers that can
separate hyperplastic/adenomatous nodules from follicu-
lar tumors can be of tremendous benefits to the patients
and the healthcare system[23]. As a result, many sur-
geries for benign lesions can be avoided and patients
can be managed medically as needed [34,23]
Galectin-3 is a beta-galactoside binding polypeptide
with a 31 kDa molecular weight. It is a member of the
lectin family, and seems to play a significant role in a
number of biological processes. It has a role in regulat-
ing cell-cell and cell-matrix interaction, adhesion,
Figure 4 Immunohistochemical stain of hyperplastic colloid
nodule shows the cells are negative for CK19 (100×).
Figure 5 Immunohistochemical stain of follicular adenoma
shows the tumor cells focally reactive for galectin-3 (100×).
Figure 6 Immunohistochemical stain of follicular adenoma
shows the tumor cells focally reactive for Ret oncoprotein
(100×).
Figure 7 Immunohistochemical stain of follicular adenoma
shows the tumor cells focally reactive for HBME-1 (100×).
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inflammation and neoplastic transformation. Normally,
it is expressed in various tissue types and tumors and
appears to have a role in the invasive and metastatic
potential of various tumors [15,20,27]. Kovacs et al
found that IHC expression of galectin-3 may help in the
differential diagnosis of solitary encapsulated follicular
lesions, especially the minimally invasive follicular carci-
noma [15]. Several other investigators showed that
galectin-3 is very useful in distinguishing benign from
malignant tumors, especially PTC, with high sensitivity
and specificity [10,17-19,34]. Galectin-3 can aid in iden-
tifying FVPC, and distinguishing minimally invasive FC
from FA. In our study, galectin-3 showed 85.2% sensitiv-
ity for immunoexpression distinction between carcino-
mas and benign nodules (positive in 27.5% of benign vs.
85.1% of malignant nodules). However, the specificity
was lower at 72.4. In addition, we found that galectin-3
was somewhat more strongly and diffusely positive in
PTC than in FC and FVPC, and expression in FA/HA
was more focal and less intense than in malignant
tumors. Also, galectin-3 expression was also detected in
8 of 52 benign non-neoplastic lesions (HN), but this was
quite focal and weak. Other authors have also noted
similar findings [3]. The positivity of galectin-3 in HN
may be explained by the fact that follicular cells nor-
mally contain endogenous biotin that can cause false
positivity. We and others also found that false positivity
can be seen in cystic and inflammatory lesions. Simi-
larly, Kovacs et al also indicated that there might be
some interpretation problems caused by the observation
of focal positivity in inflammatory and cystic lesions.
They postulated that expression of non-neoplastic folli-
cular cells in inflamed areas may result from cytokines
secreted by the inflammatory cells or simple permeation
of galectin-3 abundantly shed by lymphocytes in the
neighboring follicular cells. Therefore, they suggested
that IHC staining has to be evaluated in conjunction
with the histological features and use of biotin-free
detection system.
Figure 8 Immunohistochemical stain of follicular adenoma
shows the tumor cells focally reactive CK19 (400×).
Table 4 Sensitivity, specificity, PPV and NPV of Benign
Neoplastic (adenomas) vs. Malignant Thyroid Lesions
Markers Sensitivity Specificity PPV NPV
Gal-3 0.852 0.587 0.708 0.771
RET 0.833 0.543 0.682 0.735
HBME-1 0.870 0.435 0.644 0.741
CK-19 0.852 0.500 0.667 0.742
Gal-3, galectin-3; Ret, Ret oncoprotein; CK19, cytokeratin 19; PPV, positive
predictive value; NPV, negative predictive value.
Figure 9 Immunohistochemical stain reveals that tumor cells in
follicular carcinoma are strongly and diffusely positive for
galectin-3 (400×).
Figure 10 Immunohistochemical stain reveals that tumor cells
in follicular carcinoma are strongly and diffusely positive for
Ret oncoprotein (400×).
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lar adenoma as an indication of potentially early or inci-
pient carcinoma, in which the capsular and/or vascular
invasion can not be histologically observed yet [15].
Also, some authors believe that galectin-3 immunoex-
pression in PTC may promote the release of tumor cells
resulting in metastasis [15].
HBME-1 is a monoclonal antibody directed against an
antigen on the mesothelial cell membrane. Several stu-
dies have demonstrated its preferential reactivity in
malignant thyroid tumors [3,12,16,22,35]. It has been
found to be reactive mostly in papillary thyroid carci-
noma and some follicular carcinomas, but usually nega-
tive in follicular adenomas. Papotti et al in a study of
well-differentiated thyroid tumors of uncertain malig-
nant potential found that a diffuse and strong
expression of HBME-1, and to a lesser extent galectin-3,
is preferentially observed in the tumors with nuclear
changes suggestive of papillary carcinoma [2]. However,
they concluded that the diagnosis of these tumors
should also depend on previously defined morphologic
criteria. In our study, HBME-1 was expressed in 47 of
total 54 thyroid carcinomas with a diagnostic sensitivity
of 87%. However, it was also expressed in 9/52 (17.3%)
of benign non-neoplastic lesions and in 26/46 (56.5%) of
adenomas. Thus our study shows that HBME-1 is not a
very good marker to distinguish adenomas from thyroid
carcinomas with over half of the adenomas expressing
this marker.
Several cytokeratins have been evaluated for the differ-
ential diagnosis of thyroid nodules, of which CK19 has
been found to be the most useful. Studies showed that
Figure 11 Immunohistochemical stain reveals that tumor cells
in follicular carcinoma are strongly and diffusely positive for
HBME-1 (400×).
Figure 12 Immunohistochemical stain reveals that tumor cells
in follicular carcinoma are strongly and diffusely positive for
CK19 (400×).
Figure 13 Immunohistochemical stain reveals that the tumor
cells of classic papillary thyroid carcinoma are strongly and
diffusely positive for galectin-3 (100×).
Figure 14 Immunohistochemical stain reveals that the tumor
cells of classic papillary thyroid carcinoma are strongly and
diffusely positive for Ret oncoprotein (100×).
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thyroid tumors including classic PTC, FVPC and FC
[9,10,16,31]. However, other studies showed variable
results and yet others demonstrated that the CK19
expression is mostly focal and weak in FC, FA and
benign hyperplastic nodules [3,22,35]. Sahoo et al,
reported that 25% of their follicular adenomas had
extensive immunoreactivity for CK19, and Miettinen et
al also reported that 59% of their follicular carcinomas
showed CK19 reactivity in more than 10% of the lesions,
suggesting that CK19 expression patterns are not reli-
able for the distinction between papillary carcinomas
and follicular neoplasms [5]. In our study, 46/54 (85.1%)
of all the malignant tumors were positive for CK19 (dif-
fusely and strongly), and 23/46 (50%) of the adenomas
were also positive (but more focal and less intense). Our
results showed a higher rate of CK19 reactivity in FAs
than other studies, but the number of cases is relatively
small for making strong conclusion. Also, we observed
that positivity of CK19 in adenomas was more focal and
weak than in carcinomas. In general, although most
authors agree that CK19 reactivity is more frequent, dif-
fuse and strong in papillary carcinoma, its reactivity in
follicular neoplasms may limit its utility as a diagnostic
marker [22].
The Ret gene is located on chromosome 10 q and
encodes a tyrosine kinase transmembrane receptor [12].
It is typically absent in the normal thyroid follicular
cells; however, gene rearrangement occurs in most
PTCs. This oncogene is believed to be specific to PTC
and encodes an oncoprotein product that contains the
cytoplasmic portion of Ret gene. Therefore, some
Figure 15 Immunohistochemical stain reveals that the tumor
cells of classic papillary thyroid carcinoma are strongly and
diffusely positive for HBME-1 (100×).
Figure 16 Immunohistochemical stain reveals that the tumor
cells of classic papillary thyroid carcinoma are strongly and
diffusely positive for CK19 (100×).
Figure 17 Immunohistochemical stain shows that the tumor
cells of follicular variant of papillary carcinoma are strongly
and diffusely positive for galectin-3 (100×).
Figure 18 Immunohistochemical stain shows that the tumor
cells of follicular variant of papillary carcinoma are strongly
and diffusely positive for Ret oncoprotein (100×).
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protein is a reliable marker for PTC [12,33]. Cheung et
al showed immunoexpression of Ret in 78% of PTC,
63% of FVPC and 57% of Hurthle cell carcinoma, while
all benign nodules were non-immunoreactive for Ret. In
our study, Ret was positive in 18/20 cases of PTC, in
45/54 (83.3%) of all carcinomas, and in 30/98 (30.6%)
benign lesions. Rossie et al found that Ret had focal or
moderate immunoreactivity in benign lesions while it
showed prevalent cytoplasmic expression in classic
papillary cacrcinoma and its variants. The general con-
clusion among researchers is that diffuse immunoex-
pression represents a good supportive evidence for the
diagnosis of papillary carcinomas; however, focal stain-
ing is often found in other lesions including benign
nodules. Perhaps, a more important finding is that
immunoreactivity of a panel that includes Ret, HBME-1
and CK19 is very specific for papillary carcinoma.
Cheung et al concluded that HBME-1 positivity indi-
cates malignancy, whereas diffuse CK19 and/or Ret posi-
tivity confirm papillary differentiation [12].
Our study shows some different findings in staining
reactions with other studies. We believe that some of
the differences are due to various factors including anti-
bodies used, dilution and antigen retrieval methods, type
of tissue fixative used and time of fixation. Some
authors have also investigated the method of IHC stain-
ing and found that galectin-3 reaction may be impacted
by biotin-like activity produced by some thyroid lesions
[14]. They recommended performing galectin-3 IHC
staining of thyroid lesions using biotin-free detection
system. We believe there is a need to standardize fixa-
tion, antibody specifics, detection systems and IHC pro-
c e s s e st ob em o r ea b l et oc o m p a r er e s u l t so fv a r i o u s
studies.
Many studies have evaluated the immunoexpression of
a single marker such as galectin-3 or CK19 in the inves-
tigation of various thyroid lesions. In this study, we
aimed at evaluating multiple markers to compare their
sensitivity and usefulness, and to find out if a specific
combination of the evaluated markers (galectin-3,
HBME-1, CK-19 and Ret oncoprotein) can be of addi-
tional value in discriminating between benign and
malignant thyroid lesions. We found that these markers
combinations of galectin-3+HBME-1; galectin-3+CK19
or HBME-1+ CK19 do not improve the sensitivity or
specificity for the distinction between benign and malig-
nant thyroid lesions. Furthermore, using a combination
panel of three markers (galectin-3+ HBME-1+ CK19)
also did not increase the sensitivity or specificity for the
distinction between benign and malignant thyroid
lesions. On the other hand, other investigators have
found that panels of various combinations of IHC mar-
kers can add to the value of diagnosing malignant thyr-
oid tumors and discriminating them from benign
tumors and non-neoplastic lesions [23]. For example,
De Matos et al found that a panel of galectin-3, HBME-
1 and CK19 is useful in differentiating the follicular pat-
terned lesions, and specifically distinguishing FVTC
Figure 19 Immunohistochemical stain shows that the tumor
cells of follicular variant of papillary carcinoma are strongly
and diffusely positive for HBME-1 (400×).
Figure 20 Immunohistochemical stain shows that the tumor
cells of follicular variant of papillary carcinoma are strongly
and diffusely positive for CK19 (400×).
Table 5 Sensitivity, specificity, PPV and NPV of Benign
Non-neoplastic (HN) and Malignant Thyroid Lesions
Markers Sensitivity Specificity PPV NPV
Gal-3 0.846 0.587 0.698 0.771
Ret 0.827 0.543 0.672 0.735
HBME-1 0.827 0.435 0.623 0.690
CK-19 0.846 0.500 0.657 0.742
Gal-3, galectin-3; Ret, Ret oncoprotein; CK19, cytokeratin 19; PPV, positive
predictive value; NPV, negative predictive value.
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Page 9 of 11from FC or FA [35]. Cheung et al recommended using a
panel of CK19, HBME-1 and Ret as a useful means for
diagnosing papillary carcinoma; whereas Rossie et al
concluded that a panel of only HBME-1 and galectin-3
can correctly diagnose classic and variants of papillary
carcinomas.
In summary, immunoexpression of galectin-3, CK19
and HBME-1 is an important supplementary test in the
diagnosis of thyroid neoplasms, albeit it does not replace
the conventional histomorphological examination. We
found that these markers have somewhat similar sensi-
tivity and specificity of immunoexpression in thyroid
malignancy. We also found that combination panels of 2
or 3 of these markers (galectin-3+ HBME-1; galectin-3+
CK19; HBME-1+ CK19 or galectin-3+ HBME-1+ CK19)
do not significantly improves the sensitivity or specificity
of immunoexpression in malignant tumors. However,
using a panel of two markers is advised to avoid
instances of technical problems or processing issues.
Therefore, we recommend using these panels as useful
means to increases the likelihood of detecting malignant
tumors. This practical low cost IHC test of commer-
cially available markers can help to optimize the man-
agement of patients with thyroid nodules and reduce
unnecessary surgical resection of benign nodules. None-
theless, there are still questions to answer and additional
studies are needed toward the quest of identifying useful
markers for differentiating benign from malignant thyr-
oid nodules.
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